Tamavaq
/ Biogenea Pharmaceuticals
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
July 25, 2025
Clinical Study for the Safety and Therapeutic Efficacy of the AI-QMMM Designed TamavaqTM Personalised Vaccine in Patients With Newly Diagnosed Glioma.
(clinicaltrials.gov)
- P1 | N=29 | Recruiting | Sponsor: Biogenea Pharmaceuticals Ltd.
New P1 trial • Brain Cancer • Glioma • Oncology • Solid Tumor • CTCs
1 to 1
Of
1
Go to page
1